Tirzepatide Dosage Chart
Tirzepatide is a dual GIP and GLP-1 receptor agonist marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022, PMID 35658024) reported mean body-weight reductions of 15.0%, 19.5%, and 20.9% at 5mg, 10mg, and 15mg over 72 weeks.
Half-life
~5 days
Format
Injectable
Purity
≥99%
Protocols
6 variants
Research Protocols
Dosage Protocols
Each row reflects a common research protocol variant. These are reference ranges derived from published literature and community research — not medical guidance.
Protocol 1
Titration Step 1 (Weeks 1-4)
Dose
2.5mg subcutaneous once weekly
Duration
4 weeks
FDA-labeled starting dose. Not therapeutic by itself; the goal is GI adaptation. Inject in abdomen, thigh, or upper arm.
Protocol 2
Titration Step 2 (Weeks 5-8)
Dose
5mg once weekly
Duration
4 weeks
First maintenance-eligible dose. SURMOUNT-1 reported 15.0% mean body-weight loss at this dose at week 72.
Protocol 3
Titration Step 3 (Weeks 9-12)
Dose
7.5mg once weekly
Duration
4 weeks
Intermediate titration step before 10mg. Hold longer here if appetite suppression or GI symptoms remain meaningful.
Protocol 4
Titration Step 4 (Weeks 13-16)
Dose
10mg once weekly
Duration
4 weeks
Second maintenance-eligible dose. SURMOUNT-1 reported 19.5% mean body-weight loss at 72 weeks.
Protocol 5
Titration Step 5 (Weeks 17-20)
Dose
12.5mg once weekly
Duration
4 weeks
Final intermediate step. Most researchers hold here for at least 4 weeks before stepping to the maximum 15mg dose.
Protocol 6
Maximum Maintenance Protocol
Dose
15mg once weekly
Duration
Ongoing, reassessed quarterly
Top FDA-labeled obesity dose. SURMOUNT-1 reported 20.9% mean body-weight loss at 72 weeks. Reach only after the full stepwise titration.
Mixing Math
Reconstitution
Reference values for preparing a research vial. Adjust the syringe reading if you change the water volume.
Vial size
10mg vial (research)
BAC water
2ml bacteriostatic water
Concentration
5mg/ml
Dose / ml
2.5mg = 0.5ml · 5mg = 1.0ml · 10mg = 2.0ml
Syringe units
50 IU (2.5mg) · 100 IU (5mg) on U-100 (use 1ml syringe for 10mg+)
Frequently Paired
Common Stacks
Storage
Handling Notes
Lyophilized: 2-8°C preferred, -20°C for long-term storage. Reconstituted: refrigerate at 2-8°C and use within 28 days. Do not freeze reconstituted solution. Bring to room temperature before injection.
Research Considerations
Cautions
- Slow stepwise titration is required. SURMOUNT-1 used 4-week intervals between dose escalations.
- GI adaptation (nausea, reduced appetite, transient diarrhea or constipation) is the most common adverse effect class.
- Pancreatitis risk is non-zero across the GLP-1 / GIP class. Discontinue if persistent severe abdominal pain develops.
- Lean-mass loss tracks total weight loss. Resistance training and adequate protein intake during research are advisable.
- Pairing with cagrilintide is investigational and not FDA approved. Most published Phase 3 data uses tirzepatide as a standalone.
Ready to start your research
Get Tirzepatide from Ascension Peptides
COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.
Buy Tirzepatide nowResearch use only. Not medical advice. Browse all dosage charts